Tiziana Life Sciences Announces Findings from Intranasal Anti-CD3 mAb Treatment in Intracerebral Hemorrhage at the Annual American Academy of Neurology Conference
27 avr. 2023 07h00 HE
|
Tiziana Life Sciences Ltd.
There are no effective treatments for intracerebral hemorrhage (ICH), which has a 30% to 40% mortality rateIntranasal anti-CD3 mAb treatment showed a reduction in Intracerebral Hemorrhage injury...
Tiziana Life Sciences to File Alzheimer’s IND for Intranasal Foralumab in Q2 2023
20 avr. 2023 07h00 HE
|
Tiziana Life Sciences Ltd.
Application for $3M of non-dilutive funding for Phase 2a Alzheimer’s trial will be submitted in Q2 2023Tiziana guided by FDA Type “B” meeting comments on its scheduled Q2 2023 intranasal foralumab...
Tiziana Life Sciences Announces Invitation for Podium Presentation of Research on Intranasal Anti-CD3 mAb in Intracerebral Hemorrhage at the Annual American Academy of Neurology Conference
04 avr. 2023 10h43 HE
|
Tiziana Life Sciences Ltd.
Dr. Saef Izzy’s data shows one-month behavioral outcomes improvement in model of intracerebral hemorrhage (hemorrhagic stroke)Modulation of neuroinflammation by inducing FoxP3+ Tregs appears to have...
Tiziana Life Sciences to Proceed with Phase 2 Clinical Trial in Patients with Non-Active Secondary Progressive Multiple Sclerosis (SPMS)
28 mars 2023 07h00 HE
|
Tiziana Life Sciences Ltd.
First Phase 2 trial employing intranasal foralumab for treating inflammatory neurological diseaseTiziana received FDA Type C Meeting Minutes for proposed Phase 2 clinical trial in patients with...
Tiziana Life Sciences Highlighted in Forbes Article
17 mars 2023 07h00 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, March 17, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
Global Naloxone Market to surpass US$ 2,460.2 Million by 2030, Says Coherent Market Insights (CMI)
20 juil. 2022 09h10 HE
|
CMI
Seattle, July 20, 2022 (GLOBE NEWSWIRE) -- According to Coherent Market Insights’ analysis, the global naloxone market is estimated to be valued at US$ 1,118.3 Million in 2022 and is expected to...
Medigus: Polyrizon Signed an Agreement with Nurexone for Intranasal Administration of Cutting - Edge Therapy for Spinal Cord Injuries
18 juil. 2022 08h00 HE
|
Medigus Ltd
Polyrizon will be entitled for up to $3.35 million in addition to future royalties Tel Aviv, Israel, July 18, 2022 (GLOBE NEWSWIRE) -- Medigus Ltd. (Nasdaq: MDGS), a technology company engaged...
Ebvia Announces Positive Results Published in Nature for TMPRSS2 Inhibitor for the Prevention and Treatment of COVID-19
29 mars 2022 09h00 HE
|
Ebvia
SAN FRANCISCO, March 29, 2022 (GLOBE NEWSWIRE) -- Ebvia, a biotechnology developing simple-to-use therapeutics for the treatment and prevention of COVID-19, today announces the publication entitled...
Xanadu Bio Obtains Licenses and Options to Novel Platform Technologies from Yale University to Develop an Intranasal SARS CoV-2 mRNA Vaccine Booster Aimed at Inducing Local Mucosal Immunity to Prevent SARS CoV-2 Infection and Virus Transmission
08 févr. 2022 07h30 HE
|
Xanadu Bio
~ Company licenses PACE, a next generation polymeric nanoparticle delivery platform, and options intranasal PACE/Spike mRNA and Spike recombinant protein vaccine boosters for the treatment of...
Intranasal Drug Delivery Devices Market Size to Hit Around US$ 2.98 Billion by 2030
26 mai 2021 10h00 HE
|
Precedence Research
OTTAWA, May 26, 2021 (GLOBE NEWSWIRE) -- Precedence Research says, the global intranasal drug delivery devices market was valued at USD 1.17 billion in 2020. Drug delivery primarily refers to a...